Prevalence of KRAS G12C Mutations Across Different Populations
Description
<span data-sheets-value= "{"1":2,"2":"
This week, we’ll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.
Coverage of stories discussed this week on ascopost.com:
Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex
FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL
FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
To listen to more podcasts from ASCO, visit asco.org/podcasts.
<span data-sheets-value= "{"1":2,"2":"
This week, we’ll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.
Coverage of stories discussed this week on ascopost.com:
Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex
FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL
FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
To listen to more podcasts from ASCO, visit asco.org/podcasts.
<span data-sheets-value= "{"1":2,"2":" This week, we’ll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January. Coverage of stories discussed this week on ascopost.com: Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma To listen to more podcasts from ASCO, visit asco.org/podcasts.
<span data-sheets-value= "{"1":2,"2":" This week, we’ll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January. Coverage of stories discussed this week on ascopost.com: Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma To listen to more podcasts from ASCO, visit asco.org/podcasts.
<span data-sheets-value= "{"1":2,"2":"
This week, we’ll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we’ll hear recent news about FDA o
United States
